Home
Product
Protein
Active Protein
Other
Recombinant Human Ephrin type-A receptor 3 (EPHA3), partial (Active)

Recombinant Human Ephrin type-A receptor 3 (EPHA3), partial (Active)

CSB-MP007723HU

Rate （4.0）
Review （1）

Size:

20ug100ug1mg

US$116

Quantity:

Express system: Mammalian cell

Species: Homo sapiens (Human)

Tag Info: C-terminal 6xHis-tagged

Send an Inquiry

Start an on-line Chat

Orders can only be placed from within the U.S.

Promotion

Transmembrane Protein Questionnaire with Gifts

Product Details
Related Products
Customer Reviews and Q&A
Target Background

Product Details

Purity

Greater than 95% as determined by SDS-PAGE.
Greater than 95% as determined by SEC-HPLC.

Endotoxin

Less than 1.0 EU/ug as determined by LAL method.

Activity

①Measured by its binding ability in a functional ELISA. Immobilized EPHA3 at 2 μg/ml can bind human EFNA5(CSB-MP007464HU), the EC50 of the protein is 0.9734-1.179 ng/ml. ②Human EPHA3 protein his tag (CSB-MP007723HU) captured on COOH chip can bind Human EFNA5 protein Fc tag (CSB-MP007464HU) with an affinity constant of 13.8 nM as detected by LSPR Assay.

Target Names

EPHA3

Uniprot NO.

P29320

Research Area

Cancer

Alternative Names

AW492086; Cek4; EC 2.7.10.1; EK4; End3; Eph receptor A3; EPH-like kinase 4; EPH-like tyrosine kinase 1; EPHA3; EPHA3_HUMAN; Ephrin receptor EphA3; Ephrin type-A receptor 3; ETK 1; ETK; ETK1; HEK 4; HEK; HEK4; Human embryo kinase 1; Human embryo kinase; Mek4; MGC109882; Receptor tyrosine kinase HEK; Testicular tissue protein Li 64; Tyro 4; Tyro4; TYRO4 protein tyrosine kinase; Tyrosine protein kinase receptor ETK 1; Tyrosine-protein kinase receptor ETK1; Tyrosine-protein kinase TYRO4

Molecular Characterization

Species

Homo sapiens (Human)

Source

Mammalian cell

Expression Region

21-541aa

Target Protein Sequence

ELIPQPSNEVNLLDSKTIQGELGWISYPSHGWEEISGVDEHYTPIRTYQVCNVMDHSQNNWLRTNWVPRNSAQKIYVELKFTLRDCNSIPLVLGTCKETFNLYYMESDDDHGVKFREHQFTKIDTIAADESFTQMDLGDRILKLNTEIREVGPVNKKGFYLAFQDVGACVALVSVRVYFKKCPFTVKNLAMFPDTVPMDSQSLVEVRGSCVNNSKEEDPPRMYCSTEGEWLVPIGKCSCNAGYEERGFMCQACRPGFYKALDGNMKCAKCPPHSSTQEDGSMNCRCENNYFRADKDPPSMACTRPPSSPRNVISNINETSVILDWSWPLDTGGRKDVTFNIICKKCGWNIKQCEPCSPNVRFLPRQFGLTNTTVTVTDLLAHTNYTFEIDAVNGVSELSSPPRQFAAVSITTNQAAPSPVLTIKKDRTSRNSISLSWQEPEHPNGIILDYEVKYYEKQEQETSYTILRARGTNVTISSLKPDTIYVFQIRARTAAGYGTNSRKFEFETSPDSFSISGESSQ

Mol. Weight

61.0 kDa

Protein Length

Partial

Tag Info

C-terminal 6xHis-tagged

Buffer

Lyophilized from a 0.2 μm filtered 20 mM Tris-HCl, 0.5 M NaCl, 6% Trehalose, pH 8

Storage

Store at -20°C/-81°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Notes

Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Shelf Life

The shelf life is related to many factors, storage state, storage temperature and the stability of the product itself. Generally, the shelf life of lyophilized form is 6 months at -20°C/-80°C from the date of receipt.

Troubleshooting and FAQs

Protein FAQs

Datasheet & COA

Please contact us to get it.

Images

(Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
Activity
Measured by its binding ability in a functional ELISA. Immobilized EPHA3 at 2 μg/ml can bind human EFNA5(CSB-MP007464HU), the EC₅₀ of the protein is 0.9734-1.179 ng/ml.
Activity
Human EPHA3 protein his tag (CSB-MP007723HU) captured on COOH chip can bind Human EFNA5 protein Fc tag (CSB-MP007464HU) with an affinity constant of 13.8 nM as detected by LSPR Assay.
The purity of Human EPHA3 was greater than 95% as determined by SEC-HPLC

Description

The Human Ephrin Type-A receptor 3 (EPHA3) is a membrane tyrosine kinase receptor that promiscuously binds to ephrin family ligands. EPHA3 participates in migration and cell adhesion processes, thus mediating in the mesenchymal transition and the focal adhesion assembly. So it’s a known oncogene for colorectal cancer. This recombinant protein is expressed in mammalian cells and fused with a 6xHis-tag on the C-terminus. The expressed region is the 21-541aa of the human EPHA3 protein, with a molecular weight of 61 kDa. The purity of the final product is higher than 95%, as determined by SDS-PAGE. The biophysical parameters of this recombinant protein were tested with ELISA and LSPR. In the functional ELISA, this recombinant protein has an EC50 of 0.9734-1.179 ng/ml for the binding with human EFNA5. LSPR determines the affinity constant for the binding with human EFNA5 is 13.8 nM. This protein product can be used in ELISA and Surface Plasmon Resonance to determine the presence and concentrations of their ligands in the sample and as a control for ligand binding assays. It also can be used as an immunogen to immunize the rabbit or other animals to get corresponding antibodies and is applied to immunological studies related to immune response pathways. The final product has low levels of endotoxin, with less than 1.0 EU/µg as determined by the LAL method.

Customer Reviews and Q&A

■ Customer Reviews

Average Rating:

4.0 - 1 reviews

Submit a Review here

Applications : a:1:{i:0;a:2:{i:0;s:41:"Binding assay/Protein-protein interaction";i:1;s:0:"";}}

Review: describe

By Anonymous

Target Background

Function

Receptor tyrosine kinase which binds promiscuously membrane-bound ephrin family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Highly promiscuous for ephrin-A ligands it binds preferentially EFNA5. Upon activation by EFNA5 regulates cell-cell adhesion, cytoskeletal organization and cell migration. Plays a role in cardiac cells migration and differentiation and regulates the formation of the atrioventricular canal and septum during development probably through activation by EFNA1. Involved in the retinotectal mapping of neurons. May also control the segregation but not the guidance of motor and sensory axons during neuromuscular circuit development.

Gene References into Functions

High EPHA3 expression is associated with tumor growth and angiogenesis in gastric cancer. PMID:30066881
To investigate the relationship between five EPHA3 single nucleotide polymorphisms (SNPs) and Nonsyndromic Cleft Lip With or Without Cleft Palate (NSCL/P), EPHA3 SNPs (rs7650466, rs1398197, rs17801309, rs1054750, and rs7632427) were genotyped. The rs7650466 T allele was associated with the incidence of NSCL/P as well as with protective and dominant effects in both conditions. PMID:29932736
Although EPHA3 was reported to be one of the most frequently mutated genes in colorectal tumors, our studies using inducible isogenic cell line systems, mouse models and large human tumor collections, did not reveal a major role of this EPH receptor on proliferation/motility/invasion of cancer cells, tumor initiation/progression/metastasis in mouse models or survival of colorectal cancer patients. PMID:28169277
The interaction of AR and SP1 contributes to regulate EPHA3 expression. PMID:29917167
Findings suggest that EPH receptor A3 (EphA3) plays an important role in the pathogenesis of multiple myeloma (MM). PMID:28721629
Study shows that EphA3 is highly overexpressed in multiple myeloma (MM) and provides evidence that EphA3 plays an important role in MM angiogenesis. PMID:28415715
Results indicate that EphA3 protein expression is reduced in clear-cell renal cell carcinoma, suggesting the possibility that this receptor functions as a tumor suppressor in this disease. PMID:27591824
EphA3 promotes malignant transformation of colorectal epithelial cells by upregulating oncogenic signaling pathways. PMID:27721017
Data indicate that EPHA3 is involved in regulating the multidrug resistance (MDR) of small cell lung cancer (SCLC) via PI3K/BMX/STAT3 signaling and may be a therapeutic target in SCLC. PMID:27101199
PTP-PEST regulates EphA3 activation both by affecting cytoskeletal remodelling and through its direct action as a PTP controlling EphA3 phosphorylation. PMID:26644181
This study showed that EPHA3 gene involved in neuronal growth and cerebellum development and associated with neurological and psychological disorders. PMID:26381449
A novel association between the EPHA3 deletion and prostate cancer risk was observed in Finnish individuals. PMID:26552734
EphA3 forms dimers in the absence of ligand binding. PMID:26232493
Data indicate that hypoxia increased EphA3 receptor (EphA3) mRNA expression in EphA3+ endometrial multipotent mesenchymal stromal cells (eMSCs). PMID:25420155
EphA3 was induced by PC-1 and contributed to the malignant progression of prostate cancer PMID:25231727
Based on the knowledge that EPHA4 has been previously shown to rescue SOD1 transgenic mice from ALS phenotype and prolongs survival, EPHA3 may be a promising candidate for therepuetic interventions PMID:23991104
EphA3 may represent a novel candidate marker for patient prognosis as well a molecular target for HCC therapy. PMID:23970317
EPHA3 mutations may promote tumorigenesis only when key senescence-inducing pathways have been inactivated. PMID:23324396
EphA3 may play important roles in the angiogenesis and prognosis of gastric carcinoma PMID:22350700
High EphA3 expression is associated with glioblastoma multiforme. PMID:23410976
Cancer-associated EPHA3 mutations attenuate the tumor-suppressive effects of normal EPHA3 in lung cancer. PMID:22829656
EphA3 has ephrin- and kinase-dependent tumor suppressing activities, which are disrupted by somatic cancer mutations PMID:22242939
expression of EphA3 and CD133 in carcinoma was significantly higher than that in normal mucosal tissue PMID:21415057
Experiments in EphA3/Isl2 knock-in mice test the interactions between effects of molecular labels and correlated activity during the development of neural connectivity. PMID:21190559
Authors found significant association between the copy number variations of EphA3 and hematologic malignancies. PMID:21454190
Data shew that the identification of three novel candidates as EPH receptor genes might indicate a link between perturbed compartmentalization of early neoplastic lesions and breast cancer risk and progression. PMID:21124932
Data provide further support that ALS2CL, EPHA3, and CMYA1 are bona-fide tumor-suppressor genes and contribute to the tumorigenesis of HNSCC. PMID:20657180
EphA3, was identified as a new CD28-responsive gene in Jurkat cells by using a human cytokine/receptor array. EphA3 expression in CD28-stimulated Jurkat cells was enhanced by IGF-1 or by overexpression of the IGF-1R. PMID:14697337
Results show EPHA3 gene was implicated in the pathogenesis of lung cancer and it may be useful targets for diagnostic and therapeutic intervention in selected patients. PMID:16941478
High-resolution structures of the EphA3 kinase with and without the juxtamembrane segment allowed mapping of the coupled pathway of residues that connect the juxtamembrane segment, the activation loop, and the catalytic residues of the kinase domain. PMID:18547520
EphA3 expression may define subsets of rhabdomyosarcoma tumours, and that EphA3 suppresses motility through regulation of Rho GTPases in rhabdomyosarcoma cells. PMID:18814179
D219V missense mutation in EPHA3 is associated with hepatocellular carcinoma. PMID:19469653
mechanism of substrate binding PMID:19678838